Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implantable cardioverter-defibrillators: the second decade.

G P Fazio1, E P Veltri

  • 1Sinai Hospital of Baltimore, Maryland.

Current Opinion in Cardiology
|February 1, 1991
PubMed
Summary

Implantable cardioverter-defibrillators (ICDs) significantly reduce sudden cardiac death risk. Patient selection and programming complexity remain key considerations for this life-saving therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial.

Journal of lipid research·2009
Same author

Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia.

International journal of clinical practice·2004
Same author

Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies.

International journal of clinical practice·2003
Same author

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.

European heart journal·2003
Same author

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.

Clinical therapeutics·2001
Same author

Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?

The American journal of cardiology·1998

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Device Technology

Background:

  • Implantable cardioverter-defibrillators (ICDs) evolved from concept to clinical reality, now differentiating and treating arrhythmias.
  • ICDs have dramatically reduced sudden cardiac death risk from ~30% to ~2% at 1 year in recipients.

Purpose of the Study:

  • To review the current clinical status of ICDs.
  • To discuss ongoing controversies in patient selection and device therapy.
  • To explore future directions for ICD technology and application.

Main Methods:

  • Review of historical development and technological advancements in ICDs.
  • Analysis of clinical outcomes and survival benefits associated with ICD implantation.
  • Discussion of current controversies regarding patient selection and device programming.

Related Experiment Videos

Main Results:

  • ICDs demonstrate significant success in preventing sudden cardiac death.
  • Technological sophistication expands applicability but introduces programming challenges.
  • Controversies persist regarding optimal patient selection due to implantation risks and costs.

Conclusions:

  • ICDs are highly effective in reducing mortality from sudden cardiac death.
  • Ongoing debates focus on patient selection criteria and the impact of complex programming.
  • Future ICD development aims to enhance efficacy while addressing therapeutic challenges.